CMO
TEVA icon

Covenant Multifamily Offices’s Teva Pharmaceuticals TEVA Stock Holding History

Covenant Multifamily Offices’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,836
Closed -$29K – 179
2019
Q4 		$29K Buy
+1,836
New +$16.4K 0.01% 184
2019
Q2 		– Sell
-220
Closed -$3K – 248
2019
Q1 		$3K Buy
+220
New +$3.88K ﹤0.01% 206

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Covenant Multifamily Offices's TEVA Position: Q1 2020 in Review

Covenant Multifamily Offices sold out of Teva Pharmaceuticals (TEVA) in Q1 2020, closing a stake of 1,836 shares — an estimated $29K sold.

Covenant Multifamily Offices first reported a position in TEVA in Q1 2019 and held it in 2 quarters. The position peaked at $29K in Q4 2019. 459 funds tracked by Wall St. Rank hold TEVA as of Q1 2020.

  • Covenant Multifamily Offices reported no remaining Teva Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Covenant Multifamily Offices sold 1,836 Teva Pharmaceuticals shares in Q1 2020, an estimated $29K.
  • Covenant Multifamily Offices first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Covenant Multifamily Offices's Teva Pharmaceuticals position peaked at $29K in Q4 2019.
  • 459 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2020.

Based on Covenant Multifamily Offices's 13F filing for Q1 2020, filed 5 May 2020.